Granulocyte colony-stimulating factor (G-CSF) and granulocytemacrophage CSF are hematopoietic CSFs that stimulate proliferation, differentiation and activation of myeloid progenitor cells. 1 CSFs have primarily been used following completion of chemotherapy with the objective of reducing the duration of neutropenia. Although prophylactic CSFs can reduce infection outcomes, they do not appear to impact overall survival. 2 In addition to the prophylactic setting, CSFs also have been used in patients with acute myeloid leukemia (AML), with the aim of improving outcome by enhancing response to chemotherapy. In this setting, CSFs are administered before or concurrent with chemotherapy to increase the susceptibility of malignant cells to chemotherapy. This use of CSF has been referred to as CSF priming. 3 Several randomized controlled trials of CSF priming have been conducted in patients with AML. A relatively large study by the Dutch-Belgian Hemato-Oncology cooperative group found that G-CSF administered concurrently with chemotherapy improved disease-free survival (42 vs 33%; P ¼ 0.02) in all patients and significantly improved overall survival in standard risk patients with AML. 4 However, these positive results were tempered by several trials that did not demonstrate a benefit associated with CSF priming, thus leading to uncertainty regarding the usefulness of this intervention. We hypothesized that synthesizing the data from all randomized trials may provide a comprehensive determination of the potential efficacy of CSF priming. This information could then be used to determine whether this intervention merits further study or should be used routinely in clinical practice. In this metaanalysis, the primary objective was to determine if CSF priming is associated with improved overall survival compared with placebo or no therapy in AML patients. The secondary objectives were to determine if CSF priming improves diseasefree survival, event-free survival, remission rates and relapse risk. We also looked for specific effects of CSF priming in predefined clinically relevant subgroups.
We We defined inclusion and exclusion criteria a priori. Studies were included if (1) there was randomization between CSFs and placebo or no therapy; (2) CSFs were started before or concurrent with initiation of chemotherapy; (3) chemotherapy and other supportive care interventions were not planned to be systematically different between CSF and placebo or no therapy and (4) the study population consisted of subjects with AML. There was no language restriction for inclusion in this metaanalysis. Two reviewers (LS and RA) independently evaluated titles and abstracts of publications identified by the search strategy, and any potentially relevant publication was retrieved in full. The reviewers were not blinded to study authors or outcomes. The final inclusion of studies into the meta-analysis was by agreement of both reviewers. Agreement between reviewers on inclusion was evaluated using a k statistic. Strength of the agreement as evaluated by the k statistic was defined as slight (0.00-0.20), fair (0.21-0.40), moderate (0.41-0.60), substantial (0.61-0.80) or almost perfect (0.81-1.00). 5 The primary outcome was overall survival. Secondary outcomes were disease-free survival, event-free survival, remission rates and relapse risk. Survival outcomes were abstracted at 48 months if possible. If not available, data between 36 and 60 months were determined. Authors were contacted to obtain information not available in publications. Study quality was assessed using the Jadad scale, which examines adequacy of randomization, double blinding and a description of withdrawals and dropouts, which are elements felt to be most influential in bias. The summary Jadad scale ranges from 0 to 5; a higher score is associated with a higher quality.
This meta-analysis combined data at the study level and not at the individual patient level. Survival outcome data were synthesized using relative risk (RR) as the effect measure; an RR greater than 1 suggests that CSFs are associated with an increase in that outcome. We also described absolute risk difference for the primary outcome, with differences greater than 0 suggesting that CSFs are associated with an increase in that outcome. Effect sizes were weighted by the inverse of the variance. As we anticipated heterogeneity between studies, a random effects model 6 was used for all the analyses. We also explored the potential sources of heterogeneity with subgroup analyses by CSF type (G-CSF or granulocyte-macrophage CSF), timing of CSF administration (concurrent with chemotherapy or initiation before commencement of chemotherapy) and elderly vs non-elderly population. Elderly was defined as those more than 55-70 years of age depending on how elderly was delineated within each study. In addition, we examined outcomes in standard risk patients as defined by leukemia cytogenetics. In the stratified analyses, only outcomes (such as overall survival) in which at least two studies reported on that outcome within each stratum (for example, CSF type) were examined. This meta-analysis was performed using Review manager (RevMan) (Version 4.2, The Cochrane Collaboration, Oxford, England).
A total of 419 titles and abstracts were reviewed and 370 were excluded by initial review because they did not fulfill inclusion/ exclusion criteria. Of the 49 full papers retrieved, 30 were excluded for the following reasons: absence of placebo/no treatment arm (n ¼ 13), allocation not randomized (n ¼ 3), CSF not administered as priming (n ¼ 7), different chemotherapy (n ¼ 1) and duplicate publication or interim analysis (n ¼ 6). Thus, 19 papers satisfied predefined inclusion criteria and were included in the final meta-analysis. The reviewers had almost perfect agreement on papers for inclusion (k ¼ 0.83; 95% confidence interval (CI) 0.67-0.99). The 19 included studies and their characteristics are described in Table 1 whereas full  citations are listed in Supplementary Table 1 . These studies included 4941 participants, with 2475 randomized to CSF and 2466 to placebo or no treatment. Table 1 illustrates studies that included any elderly patients; there were six studies that exclusively enrolled this population with elderly defined as those older than 55 (n ¼ 1), 60 (n ¼ 4) and 71 (n ¼ 1) years of age. The median score for study quality using the Jadad scale was 2 (range 1-3). There was no evidence of publication bias in the primary or any of the secondary outcomes (data not shown).
Overall survival in the placebo/no treatment arms was 667/ 2257, 29.6%. Table 2 demonstrates that CSF priming did not influence overall survival, with an RR of 1.03 (95% CI 0.91, 1.17; P ¼ 0.61). The absolute risk difference was 0.01 (95% CI À0.03 to 0.05; P ¼ 0.58) Similarly, there was no significant benefit of CSF priming on disease-free survival, event-free survival, remission rates or relapse risk ( Table 2 ). In terms of subgroup analyses, only two studies reported on outcomes in standard risk patients classified by cytogenetics. 4, 7 Event-free survival was the only outcome reported by both studies and event-free survival was better with CSF priming (RR 1.41, 95% CI 1.13-1.76; P ¼ 0.002). 4, 7 There was no difference in survival by CSF type and timing of CSF administration relative to initiation of chemotherapy (data not shown). In the stratified analysis by elderly versus non-elderly population, the analysis was restricted to studies that exclusively included or excluded this population. Only overall survival and remission rate could be evaluated and neither was influenced by population age. Priming effect regarding overall survival for elderly subjects was RR 1.08, 95% CI 0.87-1.33; n ¼ 5 versus non-elderly subjects, with RR 0.92, 95% CI 0.61-1.38; n ¼ 3. Similarly, remission rates were almost identical in elderly subjects (RR 1.03, 95% CI 0.90-1.18; n ¼ 6) vs non-elderly subjects (RR 1.02, 95% CI 0.89-1.17; n ¼ 3).
Despite combining 19 trials with almost 5000 patients, CSF priming did not improve survival or remission rates in patients receiving chemotherapy for AML. Furthermore, the stratified analyses failed to show a significant difference in effect depending on CSF type, timing of CSF administration or patient age. This information is important as conflicting findings in previous trials resulted in uncertainty about the potential efficacy of this intervention.
There were not enough studies that examined intermediate risk patients classified by cytogenetics to determine whether CSF may be effective for this cytogenetic subgroup. Given that only two trials reported results in standard risk patients 4, 7 and that only event-free survival was examined by both, there is a risk of reporting bias in the publications describing this subgroup analysis. Thus, the effect of CSFs in intermediate risk patients remains unclear.
Colony-stimulating factor priming is commonly used in clinical care in at least one chemotherapy regimen, namely fludarabine and cytarabine administered with CSF priming. In one trial that randomized high-risk subjects to G-CSF priming with either cytarabine, daunorubicin and etoposide or fludarabine and cytarabine, G-CSF priming was not associated with better overall survival, with survival of 22% in each group. 8 Furthermore, the fludarabine regimen was associated with worse overall survival compared with the daunorubicin Table 1 Characteristics of included studies in the meta-analysis of priming colony-stimulating factors Number of days before initiation of chemotherapy. c Indicates whether elderly patients were included in the trial.
Table 2
Summary of outcomes in colony-stimulating factor priming versus placebo/no therapy groups
Outcome
Number of studies RR (95% CI) Letters to the Editor regimen, with survival of 16 versus 27% respectively, hazard ratio 1.33 (95% CI 1.01-1.77; P ¼ 0.05). 8 When interpreted in the context of our meta-analysis results, the trial results questions the role of fludarabine, cytarabine and priming G-CSF in patients with high-risk AML.
There are several limitations to this meta-analysis. First, the 95% CI for all survival outcomes other than remission rates does not exclude the possibility of clinically meaningful effects. However, given the point estimate of a 1% absolute risk difference in overall survival, it is unclear whether CSF priming would warrant prioritization for future study in AML trials, as a definitive trial would likely require several thousand patients. Second, the number of studies did not permit meta-regression or further stratified analyses. In addition, there was substantial heterogeneity in the types of chemotherapy administered concurrent with CSF priming. However, on balance, we did not find clinically important differences in the effect of CSF priming for the variables we examined.
In conclusion, the results of this meta-analysis demonstrate that CSF priming does not improve outcome in AML and thus should not be used in routine clinical care. Although this meta-analysis did not definitively address the question of CSF priming in standard risk patients, the overall results of the analysis do not lend strong support to study this question further. 
